Home › NDC Lookup › RxCUI directory › RxCUI 1942489

Olaparib 150 MG Oral Tablet [Lynparza] — RxCUI 1942489

Name: Olaparib 150 MG Oral Tablet [Lynparza] (RxCUI 1942489)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1942489 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1942489

Official nameOlaparib 150 MG Oral Tablet [Lynparza]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asLynparza 150 MG Oral Tablet

FDA products mapped4

Package NDCs mapped10

Reported Medicaid activity (SDUD)6,734 prescriptions · 31 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Olaparib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Olaparib (brand name Lynparza) is a targeted cancer medicine called a PARP inhibitor. It's designed for cancers in adults that carry certain DNA-repair gene mutations — most common...
What exactly is olaparib and why did my doctor prescribe it for me?
You take Lynparza tablets twice a day, and you can take them with or without food — whichever is easier for you. Swallow them whole; don't crush, chew, or break them. If you miss a...
How do I take the tablets and what should I do if I miss a dose?

📖 Read our full Olaparib guide →

🕸️ Concept Web — How Olaparib 150 MG Oral Tablet [Lynparza] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Olaparib 150 MG Oral Tablet [Lynparza] RxCUI 1942489 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Olaparib 1597582 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Lynparza 1597588 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Olaparib Oral Tablet 1942481 SCDF
- Olaparib Oral Product 1597584 SCDG
- Olaparib Pill 1597585 SCDG
- Olaparib Oral Tablet [Lynparza] 1942484 SBDF
- Lynparza Oral Product 1597591 SBDG
- Lynparza Pill 1597592 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Olaparib 150 MG Oral Tablet 1942487 SCD
- Olaparib 150 MG 1942486 SCDC
- Olaparib 150 MG [Lynparza] 1942488 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Olaparib 150 MG Oral Tablet SCD · 1942487
Olaparib 150 MG SCDC · 1942486
Olaparib Oral Tablet SCDF · 1942481
Olaparib Oral Product SCDG · 1597584
Olaparib Pill SCDG · 1597585

Brand-Name Concepts

Olaparib 150 MG [Lynparza] SBDC · 1942488
Olaparib Oral Tablet [Lynparza] SBDF · 1942484
Lynparza Oral Product SBDG · 1597591
Lynparza Pill SBDG · 1597592
Lynparza BN · 1597588

📦 FDA Products & Package NDCs

4 products · 10 package NDCs

10 package NDCs map to RxCUI 1942489 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00310-0569-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0569-12)	Lynparza	AstraZeneca Pharmaceuticals LP	2025-02-18
00310-0569-60	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-0569-60)	Lynparza	AstraZeneca Pharmaceuticals LP	2025-02-13
00310-0578-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0578-12)	Lynparza	AstraZeneca Pharmaceuticals LP	2025-02-20
00310-0578-60	60 TABLET, FILM COATED in 1 BOTTLE (0310-0578-60)	Lynparza	AstraZeneca Pharmaceuticals LP	2025-02-13
00310-0668-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0668-12)	Lynparza	AstraZeneca Pharmaceuticals LP	2017-08-17
00310-0668-60	60 TABLET, FILM COATED in 1 BOTTLE (0310-0668-60)	Lynparza	AstraZeneca Pharmaceuticals LP	2017-08-17
00310-0668-95	60 TABLET, FILM COATED in 1 BOTTLE (0310-0668-95)	Lynparza	AstraZeneca Pharmaceuticals LP	2022-09-01
00310-0679-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0679-12)	Lynparza	AstraZeneca Pharmaceuticals LP	2017-08-17
00310-0679-60	60 TABLET, FILM COATED in 1 BOTTLE (0310-0679-60)	Lynparza	AstraZeneca Pharmaceuticals LP	2017-08-17
00310-0679-95	60 TABLET, FILM COATED in 1 BOTTLE (0310-0679-95)	Lynparza	AstraZeneca Pharmaceuticals LP	2017-08-31

Observed labelers: AstraZeneca Pharmaceuticals LP (10) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.